Glioblastoma – Current Concepts, Prognostic Markers And Molecular Classification

Arvids Jakovlevs; Andrejs Vanags; Dainis Balodis; Janis Gardovskis; Ilze Strumfa

doi:10.2478/chilat-2014-0012

Abstract

Glioblastoma (GBM) has very poor prognosis despite aggressive therapy including surgical treatment. At present, few molecular markers could clarify GBM prognosis in greater detail. However, better understanding of the molecular pathogenesis would be the mainstay of improved, more personalized treatment modalities. Recent large-scale molecular studies brought new data that altered previous concepts about GBM; even molecular subtypes of GBM have been discovered. We discuss here the classic pathology of GBM along with molecular markers and subtypes of GBM as well as routine applications of these advances.

References

1. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance // J Neuropathol Exp Neurol, 2004; 63(7):700 - 707
Search in Google Scholar
2. Bailey PC, Cushing H. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis // Can Med Assoc J, 1926; 16:872
Search in Google Scholar
3. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133() glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles // Cancer Res, 2007; 67(9):4010 - 4015
Search in Google Scholar
4. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis // Acta Neuropathol, 2010; 119(4):509 - 511
Search in Google Scholar
5. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach // Acta Neuropathol, 2008; 115(2):249 - 259
Search in Google Scholar
6. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas // J Neurooncol, 2008; 90(2):157 -170
Search in Google Scholar
7. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR, Gillespie GY. CD133 is a marker of bioenergetic stress in human glioma // PLoS ONE, 2008; 3:11
Search in Google Scholar
8. Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method // Cancer, 1988; 62:2152 -2165
Search in Google Scholar
9. Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas // Expert Rev Vaccines, 2012; 11(2):133 - 144
Search in Google Scholar
10. Fischer I, de la Cruz C, Rivera AL, Aldape K. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH) // Diagn Mol Pathol, 2008; 17(4):227 - 230
Search in Google Scholar
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma // N Engl J Med, 2005; 352:997 - 1003
Search in Google Scholar
12. Kim W, Liau LM. IDH mutations in human glioma // Neurosurg Clin N Am, 2012; 23(3): 471 - 480
Search in Google Scholar
13. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concepts to clinical diagnosis // Neuro Oncol, 1999; 1:44 - 51
Search in Google Scholar
14. Le Mercier M, Hastir D, Moles Lopez X, de Nève N, Maris C, Trepant AL, Rorive S, Decaestecker C, Salmon I. A simplified approach for the molecular classification of glioblastomas // PLoS ONE, 2012; 7:9
Search in Google Scholar
15. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Isral MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme // Proc Natl Acad Sci U S A, 2005; 102(16): 5814 - 5819
Search in Google Scholar
16. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cell in glioblastoma // Mol Cancer, 2006; 5:67
Search in Google Scholar
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Astrocytic tumors // Bosman FT, Jaffe ES, Lakhani RS, Ohgaki H. WHO classification of tumours of the central nervous system. 3rd edition. Lyon: IARC, 2007; 13 - 52
Search in Google Scholar
18. Loussouarn D, le Loupp AG, Frenel JS, Leclair F, von Deimling A, Aumont M, Martin S, Campone M, Denis MG. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for detection of IDH1 mutations in gliomas // Int J Oncol, 2012; 40(6):2058 - 2062
Search in Google Scholar
19. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Identification of molecular subtypes of glioblastoma by gene expression profiling // Oncogene, 2003; 22(15):2361 - 2373
Search in Google Scholar
20. Miyuki U, Mieko S, Oba S, Anamaria AC, Moura RP, Henrique PA, Navarro HC, Begnami M, Rosemberg S, Teixeira MJ, Nagahashi KS. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma // Clinics (Sao Paulo), 2011; 66(10):1747 - 1755
Search in Google Scholar
21. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges // Semin Oncol, 2011; 38(2):243 - 253
Search in Google Scholar
22. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification // Cancer Res, 2003; 63(7):1602 - 1607
Search in Google Scholar
23. Ohgaki H, Kleihues P. Genetic pathways of primary and secondary glioblastoma. Am J Pathol, 2007; 170(5):1445 - 145310.2353/ajpath.2007.070011185494017456751
Search in Google Scholar
24. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, de Maria R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme // Clin Cancer Res, 2008; 14:8205 -8212
Search in Google Scholar
25. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme // Science, 2008; 321(5897):1807 -1812
Search in Google Scholar
26. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma // Clin Cancer Res, 2005; 11:3326 - 3334
Search in Google Scholar
27. Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma // Cancer, 2004; 101:2318 - 2326
Search in Google Scholar
28. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis // Cancer Cell, 2006; 9(3):157 - 173
Search in Google Scholar
29. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M. Anti-O6-methylguaninemethyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker // Brain Pathol, 2008; 18:520 -532
Search in Google Scholar
30. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme // Cancer Res, 2003, 63:6962 - 6970
Search in Google Scholar
31. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells // Nature, 2004; 432(7015):396 - 401
Search in Google Scholar
32. Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer // Biochem Cell Biol, 2005; 83(4):429 - 437
Search in Google Scholar
33. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma // N Engl J Med, 2005; 352:987 - 996
Search in Google Scholar
34. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed T, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 // Cancer Cell, 2010; 17(1):98 - 110
Search in Google Scholar
35. Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, Jones C, Reis RM. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas // Anticancer Res, 2008; 28(2):913 - 920
Search in Google Scholar
36. Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, Pai PC, Shin JW. Evaluation of the prognostic value of CD44 in glioblastoma multiforme // Anticancer Res, 2010; 30(1):253 - 259
Search in Google Scholar

Glioblastoma – Current Concepts, Prognostic Markers And Molecular Classification

Abstract

Paradigm

My account